James Brumley

James Brumley

InvestorPlace Feature Writer

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Should I Buy Yum! Brands? 3 Pros, 3 Cons

By James Brumley, InvestorPlace Feature Writer

Health scares in China put the jitters into YUM shareholders, but the company's ability to consistently generate earnings and produce blockbuster products will see it through.

Zynga: Jerk … or Just Capitalistic?

By James Brumley, InvestorPlace Feature Writer

Some of the world’s best companies have gained success by borrowing someone else’s idea and making it a little better and more economical. Zynga's no different.

Bank ‘Stress Tests’ Reveal Winners and Losers

By James Brumley, InvestorPlace Feature Writer

The Fed was kind enough to do a little research for you -- here's what you should know before investing in the financial space.

Icahn Proves Being a Shareholder Ain’t What It Used to Be

By James Brumley, InvestorPlace Feature Writer

Icahn's saber-rattling over a special Dell dividend belies a larger problem: Large, vocal and well-funded investors continue to chip away at the rights of smaller shareholders.

New Highs for the Dow Jones: A Perfect Reason to Stay Away

By James Brumley, InvestorPlace Feature Writer

With so many profits ready to be locked in, the move into all-time-high territory is more likely to start a profit-taking wave than it is to pull in more buyers.

An HIV ‘Cure’? Let’s Not Overstate the Success

By James Brumley, InvestorPlace Feature Writer

Merck, J&J and others won't be dropping their research to recreate the success seen in the early treatment of an HIV-positive child.

Should I Buy McDermott? 3 Pros, 3 Cons

By James Brumley, InvestorPlace Feature Writer

McDermott International's Q4 numbers are strong, but revenues are still expected to slide despite a growing number of backlogged projects.

When Will Ackman Finally Lose His Patience?

By James Brumley, InvestorPlace Feature Writer

Ron Johnson appears to be running JCPenney into the ground, but Bill Ackman is likelier than not to give the CEO a few more quarters to play.

Will Higher Payroll Tax Rates Really Crimp Consumer Spending?

By James Brumley, InvestorPlace Feature Writer

While retailers might have enjoyed a tailwind at the end of 2012, they’ve hit a headwind since Jan. 1 that isn’t showing up in the numbers.

Why RadioShack Will Be Dead By 2015

By James Brumley, InvestorPlace Feature Writer

The good news is RadioShack can and will sell assets and close stores if it needs to shore up waning liquidity. The bad news is, that’s the only good news.

Load More